Biocon announces pivotal clinical data for Yesafili biosimilar
Biocon announces pivotal clinical data for Yesafili biosimilar. Biocon has announced the publication of pivotal clinical data supporting the effectiveness of Yesafili, its biosimilar to Eylea® (Aflibercept), in a press release dated July 09, 2026. The data reinforces the drug’s potential in ophthalmic indications and could support future regulatory approvals and market expansion. Positive clinical outcomes may enhance commercial prospects in the growing biosimilars market.
📊 STOCKS: BIOCON | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #Pharma
Stocks mentioned
⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.
Trade smarter on NSE
Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.
Start for ₹1 →